KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19

KIR+CD8+ T细胞抑制致病性T细胞,并在自身免疫性疾病和COVID-19中发挥作用。

阅读:2
作者:Jing Li ,Maxim Zaslavsky ,Yapeng Su ,Jing Guo ,Michael J Sikora ,Vincent van Unen ,Asbjørn Christophersen ,Shin-Heng Chiou ,Liang Chen ,Jiefu Li ,Xuhuai Ji ,Julie Wilhelmy ,Alana M McSween ,Brad A Palanski ,Venkata Vamsee Aditya Mallajosyula ,Nathan A Bracey ,Gopal Krishna R Dhondalay ,Kartik Bhamidipati ,Joy Pai ,Lucas B Kipp ,Jeffrey E Dunn ,Stephen L Hauser ,Jorge R Oksenberg ,Ansuman T Satpathy ,William H Robinson ,Cornelia L Dekker ,Lars M Steinmetz ,Chaitan Khosla ,Paul J Utz ,Ludvig M Sollid ,Yueh-Hsiu Chien ,James R Heath ,Nielsen Q Fernandez-Becker ,Kari C Nadeau ,Naresha Saligrama ,Mark M Davis

Abstract

In this work, we find that CD8+ T cells expressing inhibitory killer cell immunoglobulin-like receptors (KIRs) are the human equivalent of Ly49+CD8+ regulatory T cells in mice and are increased in the blood and inflamed tissues of patients with a variety of autoimmune diseases. Moreover, these CD8+ T cells efficiently eliminated pathogenic gliadin-specific CD4+ T cells from the leukocytes of celiac disease patients in vitro. We also find elevated levels of KIR+CD8+ T cells, but not CD4+ regulatory T cells, in COVID-19 patients, correlating with disease severity and vasculitis. Selective ablation of Ly49+CD8+ T cells in virus-infected mice led to autoimmunity after infection. Our results indicate that in both species, these regulatory CD8+ T cells act specifically to suppress pathogenic T cells in autoimmune and infectious diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。